1. Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
- Author
-
Zay Htet and Mahzuz Karim
- Subjects
medicine.medical_specialty ,030209 endocrinology & metabolism ,Disease ,030204 cardiovascular system & hematology ,Diabetes Complications ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Diabetes mellitus ,medicine ,Empagliflozin ,Humans ,In patient ,Dapagliflozin ,Intensive care medicine ,Sodium-Glucose Transporter 2 Inhibitors ,Canagliflozin ,business.industry ,General Medicine ,medicine.disease ,chemistry ,Diabetes Mellitus, Type 2 ,Novel agents ,Cardiovascular Diseases ,Relative risk ,business ,medicine.drug - Abstract
Recent years have seen a paradigm shift in the management of patients with diabetes mellitus. Rather than good glycaemic control being the sole primary aim, the therapeutic focus has broadened to consider potential additional cardiovascular and renal benefits. Sodium-glucose co-transporter 2 inhibitors, such as empagliflozin, canagliflozin and dapagliflozin, have gained increasing prominence, with evidence suggesting significant improvement in outcomes in patients with established cardiovascular and renal disease. Here, we discuss the benefits and relative risks of these novel agents and highlight important clinical issues of relevance to general physicians.
- Published
- 2024